Kimura Ayako, Nakagomi Hiroshi, Inoue Masayuki, Oka Tomomi, Hirotsu Yosuke, Amemiya Kenji, Mochizuki Hitoshi, Oyama Toshio, Omata Masao
Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.
Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Int Cancer Conf J. 2024 May 11;13(3):193-198. doi: 10.1007/s13691-024-00685-3. eCollection 2024 Jul.
A 61-year-old woman with pathogenic variant had been treated for 20 years and showed dynamic changes in the genomic profile of her metachronous bilateral breast cancer and metastases. She underwent right breast conservation surgery at age 42-Genome 1, lung metastasis and left axillary lymph node metastasis at age 51, partial excision under local anesthesia for left breast cancer at age 53-Genome 2, left axillary lymph node dissection was added 6 month later-Genome 3. Then, olaparib was administered, and subsequently, left mastectomy was performed for the recurrence of left breast cancer at age 59-Genome 4. Genomic profile of the tumor was analyzed at four points (Genome 1-3 were analyzed by in house breast cancer panel, and Genome 4 was analyzed by Foundation One CDx). Two interesting findings emerged from these analyses. First, the genomic profile revealed that the left axillary lymph node metastasis, considered histologically from right breast cancer, was a metastasis from the left breast cancer. The second finding is that as the disease progressed, mutation profile became more diverse. The profile of the left breast cancer removed after olaparib and other treatments showed reversion mutation of and was diagnosed as tumor mutation burden high. Subsequent response to pembrolizumab was favorable.
一名携带致病变异的61岁女性已接受治疗20年,其异时性双侧乳腺癌及转移灶的基因组图谱呈现动态变化。她42岁时接受了右乳保乳手术——基因组1,51岁时出现肺转移和左腋窝淋巴结转移,53岁时因左乳腺癌在局部麻醉下进行了部分切除——基因组2,6个月后增加了左腋窝淋巴结清扫术——基因组3。然后,给予奥拉帕利治疗,随后,59岁时因左乳腺癌复发进行了左乳房切除术——基因组4。在四个时间点对肿瘤的基因组图谱进行了分析(基因组1 - 3通过内部乳腺癌检测板进行分析,基因组4通过Foundation One CDx进行分析)。这些分析得出了两个有趣的发现。首先,基因组图谱显示,从组织学上看被认为是右乳腺癌转移的左腋窝淋巴结转移,实际上是左乳腺癌的转移。第二个发现是,随着疾病进展,突变谱变得更加多样化。在接受奥拉帕利和其他治疗后切除的左乳腺癌的图谱显示了 的回复突变,并被诊断为肿瘤突变负荷高。随后对帕博利珠单抗的反应良好。